Supporting Results

siRNA encapsulation efficiencies by aldehyde/sulfate latex beads assay
To reassure the siRNA encapsulation into Z HER2-ΔHBc particles, we performed a beads coupling study with HBc-siRNA hybrid particles. siNEG Att0655 was encapsulated into Z HER2 -ΔHBc AF480 particles at 1:1 HBc:siRNA molar ratio and coupled with aldehyde/sulfate latex beads ( Figure S2) . The aldehyde/sulfate latex contains high density of aldehyde groups grafted to the surface of the polymer particle, which enables facile coupling of proteins. This will allow the nano-sized HBc particles to be detected using flow cytometry. According to flow cytometry analysis (Figure S2) , only beads coupled with Z HER2 -ΔHBc AF480 particles showed enhanced in median fluorescent intensity (MFI) in FL-1 channel (green bars), whereas S-3 the untreated beads, which acted as a negative control, did not show any significant increase. These results indicated that the aldehyde/sulfate latex beads were successfully coupled with Z HER2 -ΔHBc AF480 particles. Meanwhile, 1.4-and 1.5-fold increases (blue dots) in MFI in FL-4 channel of was observed when siNEG Att0655 was encapsulated into Z HER2 -ΔHBc AF480 particles, using Method I or Method II, respectively. However, as shown in Figure 1B , a 2.7-fold increase in MFI (blue dot) was observed for HBc-siRNA particles prepared by Method III. Taken together, these results indicate that the HBc particles could encapsulate siRNA into their interior. Moreover, the siRNA encapsulated using Method III showed the highest amount of siRNA encapsulated into HBc particles, compared to the other HBc-siRNA hybrid particles prepared by Method I and Method II. This result is in agreement with the results obtained by gel retardation assay (Figure 1) , which also show that approximately 1 mol of siRNA is encapsulated in 1 mol HBc particles when encapsulated using Method III.
Method III will be used later to encapsulate siRNA into HBc particles for further studies.
In vitro cellular uptake HBc-siRNA hybrids subjected to serum competition
The intracellular uptake of HBc-siRNA hybrid particles in vitro in cancer cells were further studied subjected to serum competition. Cell uptake was evaluated using flow cytometry detected at FL-1 and FL-4 channels, and expressed as the fold increase in median fluorescent intensity (MFI). MDA-MB-468 (HER2 -) and SKBR-3 (HER2 +++ ) cells were treated with Lipofectamine®-siNEG Atto655 complexes or Z HER2 -ΔHBc AF488 -siNEG Atto655 hybrids at 1 or 24 h post incubation in the media ± 10% serum. As shown in Figure S3 , by FL-1 detector, a significantly decreased cellular uptake was observed when MDA-MB-468 (light blue bars) or SKBR-3 (light green bars) cells were treated with Z HER2 -ΔHBc AF488 -siNEG Atto655 hybrids in serum-containing media, compared to those treated in serum-free media. Furthermore, uptake of siNEG Atto655 detected by FL-4 channel also showed significant reduction (dark bars) when both cell lines were treated in serum condition.
The same result was observed when cells were treated with Lipofectamine®-siNEG Atto655 complexes. These results suggested that the presence of serum did affect and reduce the intracellular uptake in cancer cells; however, the uptake of siRNA could be still observed.
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Figure S1. A scheme summarizing methods used for siRNA encapsulation into HBc particles. siRNA was encapsulated into Z HER2 -ΔHBc using one of the three different methods, dis-assembly/re-assembly by urea, osmotic shock or dis-assembly/re-assembly by DTT/CaCl 2 , namely as Method I, Method II and Method III. Figure S2 . Confirmation of siNEG Atto655 encapsulation with beads coupling method. A scheme summarising HBcsiNEG coupling method to the aldehyde sulphate latex beads for confirmation of siNEG encapsulation. hybrids, in the media ± 10% serum. Cellular uptake was assessed using flow cytometry at 1 or 24 h post incubation. A slight but significant reduction in uptake of HBc and siRNA was observed for both cell lines in presence of serum. Values are expressed as fold increase in MFI ± SD (n = 3). **p < 0.01, ***p < 0.001, relative to naïve (one-way ANOVA test). Treatment groups including PBS, Z HER2 -ΔHBc-siNEG (4 µg siNEG/mouse), ΔHBc-siPLK1 (4 µg siPLK1/mouse) and Z HER2 -ΔHBc-siPLK1 (4 µg siPLK1/mouse). GAPDH gene was used as a control housekeeping gene. Protein levels of PLK1 were reduced in the case of Z HER2 -ΔHBc-siPLK1 compared to PBS. **p < 0.01 (one-way ANOVA test). Data was expressed as mean ±SD (n=6).
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S-8 Figure S5 . Assessment of total body weight of HER2-expressing intraperitoneal tumor-bearing mice models. NSG mice (n=7) were intraperitoneally injected with 5.0 ×10 6 MDA-MB-435-MLE cells. Mice were treated with PBS, Z HER2 -ΔHBc-siNEG (4 µg siNEG/injection/mouse), ΔHBc-siPLK1 (4 µg siPLK1/injection /mouse) and Z HER2 -ΔHBc-siPLK1 (4 µg siPLK1/mouse), intraperitoneally. Seven treatments were given intraperitoneally at 3 days' intervals, commencing on day 4 post-tumor inoculation. No significant different of total body weight between treatment groups were observed. Data was expressed as mean ± SD (n=7).
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Figure S6. TNF-α cytokine levels in serum after treatment. TNF-α cytokine levels were assessed in serum samples in MDA-MB-435-MLE tumor-bearing NSG mice by ELISA. Serums were sampled at day 28 after 7 treatments of PBS, Z HER2 -ΔHBc-siNEG (4 µg siNEG/injection/mouse), ΔHBc-siPLK1 (4 µg siPLK1/injection /mouse) and Z HER2 -ΔHBc-siPLK1 (4 µg siPLK1/mouse), were given intraperitoneally at 3 days' intervals, commencing on day 4 post-tumor inoculation. Data was expressed as mean ±SD (n=7). ***p < 0.001, relative to group of LPS (one-way ANOVA test). 
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